VIDEO: Risankizumab bests placebo at 52 weeks in UC, regardless of induction outcomes
Click Here to Manage Email Alerts
Key takeaways:
- Risankizumab topped placebo in endoscopic improvement and remission at 52 weeks, regardless of induction outcomes.
- Risankizumab 360 mg outperformed 180 mg in those without positive induction outcomes.
PHILADELPHIA — Risankizumab outperformed placebo in endoscopic improvement and remission through 52 weeks of maintenance therapy in moderately to severely active ulcerative colitis, regardless of induction outcomes, according to data.
In a post-hoc analysis of the phase 3 COMMAND study, Remo Panaccione, MD, FRCPC, professor of medicine and director of the Inflammatory Bowel Disease Unit at the University of Calgary, and colleagues reported outcomes of clinical remission or endoscopic improvement through 52 weeks of maintenance after 12 weeks of induction.
Clinical responders to 1,200 mg IV risankizumab (Skyrizi, AbbVie) from the INSPIRE study were randomly assigned to subcutaneous risankizumab 180 mg (n = 178) or 360 mg (n = 185) or placebo (n = 181) every 8 weeks in the COMMAND study.
Of those in clinical remission at week 0, more patients on risankizumab 180 mg and 360 mg achieved endoscopic improvement at week 52 vs. placebo (79.3% and 55% vs. 43.4%, respectively), as well as endoscopic remission (53.3% and 27.5% vs. 22.6%) or histological-endoscopic mucosal healing (69.8% and 52.5% vs. 35.8%).
Results were similar among those with endoscopic improvement at week 0 (73.6% and 54.1% vs. 47.4%; 46.7% and 31.3% vs. 23.1%; and 66.7% and 50.9% vs. 37.2%).
However, among those who did not achieve clinical remission or endoscopic improvement at week 0, outcomes were better for patients on risankizumab 360 mg vs. 180 mg.
“If you were in clinical remission or had endoscopic response at the end of 12 weeks, those patients tended to do better numerically at the end of maintenance,” Panaccione said. “But equally, if not more important, if you look at the patients who did not achieve clinical remission or who did not achieve endoscopic response at the end of 12 weeks ... 360 mg subcutaneous dose every 8 weeks actually performed better.”
Collapse
Panaccione R, et al. Efficacy of risankizumab maintenance therapy by clinical remission and endoscopic improvement status in patients with moderately to severely active ulcerative colitis: Post hoc analysis of the COMMAND phase 3 study. Presented at: ACG Annual Scientific Meeting; Oct. 25-30, 2024; Philadelphia (hybrid meeting).
Read more about
Click Here to Manage Email Alerts